Evidence map›Paper›PMID 34813941›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2022

Symptom Classes in Decompensated Liver Disease.

Lissi Hansen, Michael F Chang, Shirin Hiatt, Nathan F Dieckmann, Arnab Mitra, Karen S Lyons, Christopher S Lee

Abstract read
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lissi HansenSchool of Nursing, Oregon Health and Science University, Portland, Oregon. Electronic address: hansenli@ohsu.edu.
Michael F ChangGastroenterology and Hepatology, VA Portland Health Care System, Portland, Oregon.
Shirin HiattSchool of Nursing, Oregon Health and Science University, Portland, Oregon.
Nathan F DieckmannSchool of Nursing, Oregon Health and Science University, Portland, Oregon.
Arnab MitraDivision of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon.
Karen S LyonsWilliam F. Connell School of Nursing, Boston College, Boston, Massachusetts.
Christopher S LeeWilliam F. Connell School of Nursing, Boston College, Boston, Massachusetts.

Funding

Symptom burden in End-Stage Liver Disease patient-caregiver dyadsR01NR016017 · NINR · OREGON HEALTH & SCIENCE UNIVERSITY · PI HANSEN, LISSI · 2016 to 2020
$1.9M
NINR NIH HHS R01 NR016017
6 · The paper itself

Abstract

BACKGROUND &

aimsPatients with decompensated liver disease have been categorized by disease severity. This analysis sought to classify patients with end-stage liver disease based on symptoms rather than disease state and to identify distinct severity classes of physical and psychological symptoms.

methodsPatients with a model for end-stage liver disease-sodium score of 15 or higher were recruited from liver clinics in 2 health care organizations. They completed the Condensed Memorial Symptom Assessment Scale, Revised Ways of Coping Checklist, Patient Health Questionnaire, Life Orientation Test-Revised, and the Short-Form Health Survey. Cross-sectional data were analyzed using latent class mixture modeling.

resultsThe sample (N = 191; age, 56.6 ± 11.1 y; 33.5% ETOH; 28.3% nonalcoholic fatty liver disease; 13.1% autoimmune/primary biliary cholangitis/primary sclerosing cholangitis) was predominantly male (64.2%), Child-Turcotte-Pugh class C (49.5%), with an average model for end-stage liver disease-sodium score of 18.7 ± 4.9. Three distinct classes of symptoms were identified, as follows: mild (26.7%), moderate (41.4%), or severe (31.9%) symptoms. Symptom classes were independent of disease severity and demographic characteristics, except age. All Condensed Memorial Symptom Assessment Scale symptoms and Patient Health Questionnaire scores were significantly different across the 3 classes (P < .05). The symptom classes also differed significantly in physical and mental quality of life, optimism, and avoidance coping behaviors (all P < .001).

conclusionsPatient-reported symptom severity occurred independent of disease severity, contrary to common assumptions. Focusing on the moderate and severe symptom classes as well as patient history of end-stage liver disease complications may enhance providers' ability to improve symptom management for this population.

Indexed as

End Stage Liver DiseaseLiver DiseasesAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuality of LifeSeverity of Illness IndexSodiumSodiumDecompensated Liver DiseaseDepressionQuality of LifeSymptom Distress

Identifiers

PMID34813941
PMCPMC9120261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.